Ethical Clearance

IJPRISETCML- Virtue Datasys Scientific Research, Innovation and Publication Solutions insists the authors to get necessary approval from the Institutional Ethics Committees/Institutional Review Boards/Ethics Committees (ECs). For Experiments involving humans or human samples or Data. The authors need to disclose such approval by indicating the Reference number and date of issue. The Ethical approval level may vary as per the geographical jurisdiction, but IJPRISETCML- Virtue Datasys Scientific Research, Innovation and Publication Solutions insists authors to follow the SCOPE guidelines for ethical clearance  

Experiments involving Cell lines:

When cell lines of cancer derivatives used, the authors should disclose the source of supply with reference number; if gifted by someone, the original source should be disclosed; a written consent should be provide if it is of human origin. In all these cases, an Institutional

ethical committee’s approval must be obtained. 

Experiments involving Plant:

IJPRISETCML- Virtue Datasys Scientific Research, Innovation and Publication Solutions recommends for authors to comply with Convention on the Trade in Endangered Species of Wild Fauna and Flora and the Convention on Biological diversity when wild and endangered plants are used as study materials. Necessary National or institutional permission should have obtained while using infected plants or infecting the plants with endemic pathogens.

 For Clinical Protocols

Clinical study-based manuscripts should SPIRIT (http://www.spirit-statement.org/) protocols 

Clinical Trial Policy

IJPRISETCML- Virtue Datasys Scientific Research, Innovation and Publication Solutions publication follows World Health Organisation (WHO) guidelines for a clinical study: “Any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells, and other biological products, surgical procedures, radiological procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. This definition includes Phase I and Phase IV trials”.